Tirzepatide (Mounjaro) is a once-weekly GLP-1/GIP medication that may help eligible patients manage appetite, support weight loss, and improve long-term weight management under medical supervision
Persistent vomiting (unable to keep down food or fluids for more than 24 hours) requires prompt medical attention, as it can lead to dehydration and electrolyte imbalances, potentially causing acute kidney injury
5 This approach incorporates treatment directed to optimise lifestyle factors, targeted pharmacological therapy to preserve end-organ function and additional therapies to address risk factors such as glycaemia, hypertension and dyslipidaemia
The FDAs requirements for obesity drugs include demonstration of clinically meaningful weight loss versus placebo, an acceptable safety profile, and sufficient long-term data
Use the top edge of the plunger stopper to measure accurately (e.g., 10 units = 0.1 mL)